SELECTIVE TARGETING OF AMYLOID-BETA OLIGOMER SPECIES BY PMN310, A MONOCLONAL ANTIBODY RATIONALLY DESIGNED FOR GREATER THERAPEUTIC POTENCY IN ALZHEIMER’S DISEASE